Join
Live feed
·
PRReleasevia Quantisnow
Xencor Inc. logo

Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs

ByQuantisnow·Wall Street's wire, on your screen.
XNCR· Xencor Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track XNCR (Xencor Inc.) and more on Quantisnow.